Managing Partner, Harris Kaplan, joins industry experts in FirstWord ExpertViews: The Future Impact of the Inflation Reduction Act on Pharma Drug Pricing
- Jun 4
- 1 min read
The decisions that shape commercial success are increasingly being made long before launch. As the Inflation Reduction Act continues to influence pricing, access, and reimbursement dynamics, companies must consider how evidence generation, differentiation, and value communication fit into their development strategy from the outset.
In FirstWord's ExpertViews report, The Future Impact of the Inflation Reduction Act on Pharma Drug Pricing, Harris Kaplan shares his perspective alongside other industry experts on the evolving implications of the IRA for pharmaceutical manufacturers and the broader healthcare ecosystem.
